Janux Therapeutics, Inc. — Q2 2021 Form 10-Q
Reporting period: Three and six months ended June 30, 2021. Janux is a preclinical-stage biopharmaceutical company developing cancer therapeutics using its TRACTr platform. Its candidates were in preclinical or discovery stages, and it had no approved products or product-sale revenue.
Financial results and liquidity
Amounts below are in millions of dollars, except per-share data. Q2 means the three months ended June 30; H1 means the six months ended June 30.
| Metric | Q2 2021 | Q2 2020 | H1 2021 | H1 2020 |
|---|---|---|---|---|
| Collaboration revenue | $0.482 | $0 | $0.862 | $0 |
| Research and development expense | $4.737 | $0.673 | $6.662 | $1.222 |
| General and administrative expense | $1.997 | $0.433 | $2.736 | $0.710 |
| Operating loss | $(6.252) | $(1.106) | $(8.536) | $(1.932) |
| Net loss | $(6.206) | $(2.460) | $(8.490) | $(3.873) |
| Basic and diluted net loss per share | $(0.62) | $(2.76) | $(1.52) | $(4.52) |
- At June 30, cash and cash equivalents were $251.6 million and short-term investments were $142.6 million, totaling approximately $394.2 million. Total current assets were $396.6 million; current liabilities were $9.2 million.
- H1 operating cash use was $0.6 million, investing cash use was $142.8 million, and financing cash provided was $387.2 million. Cash and cash equivalents increased $243.8 million during H1.
- Total liabilities were $12.0 million, primarily deferred revenue; the balance sheet lists no borrowings or convertible notes at June 30. Convertible preferred stock converted to common stock in connection with the IPO.
- Profitability and operating margins are not meaningful for this development-stage company with no product sales. H1 accumulated deficit was $23.2 million.
Material changes versus prior comparable periods
- Revenue began in 2021 under the Merck collaboration: $0.482 million in Q2 and $0.862 million in H1, versus none in 2020.
- H1 R&D expense rose $5.4 million and G&A expense rose $2.0 million year over year. Management attributed the increases to development activity, personnel and facilities, stock-based compensation, licensing, and public-company-related professional costs. H1 stock-based compensation was $1.4 million versus $0.004 million in 2020.
- H1 net loss increased to $8.5 million from $3.9 million. The comparison was partly affected by 2020 interest expense and fair-value charges on convertible notes, which had converted into preferred stock in June 2020.
- In March and April 2021, preferred-stock sales generated approximately $180.5 million net. The June IPO sold 13.11 million shares at $17 per share; the filing reports approximately $204.1 million net proceeds. The company said $0.9 million of IPO costs remained unpaid at June 30.
Outlook, commentary, risks, and unusual items
- Management expected substantial operating losses and increased expenses for the foreseeable future, with additional financing likely needed to advance candidates through development and commercialization. It estimated existing cash and investments would fund operations for at least 12 months, but stated these resources would not fund candidates through regulatory approval.
- Janux expected to submit at least two IND applications by the end of 2022. Lead programs target PSMA, EGFR, and TROP2; all programs were preclinical or discovery-stage. This is a development milestone, not financial guidance.
- Under its Merck agreement, Merck may select up to two targets; one had been selected. Janux is eligible for up to $500.5 million per target in upfront and milestone payments, plus royalties. These are contingent potential payments, not committed revenue. Merck-related deferred revenue was $7.9 million at June 30, including $5.1 million current.
- Management cited uncertainty around preclinical and clinical success, regulatory approval, manufacturing and third-party dependencies, financing needs, intellectual-property protection, competition, and possible COVID-19 effects on operations and development timelines. It stated the extent of any COVID-19 impact remained uncertain.
- A WuXi Biologics license supports manufacturing components for PSMA-TRACTr and EGFR-TRACTr. Janux paid a $0.2 million one-time fee and may owe low-single-digit royalties on certain sales if it uses a third-party manufacturer rather than WuXi; buyout options are available under the agreement.
- The company reported no material legal proceedings. Disclosure controls were judged effective; management had not yet been required to assess internal control over financial reporting as a newly public company.
Most important facts for investors to verify
- Whether preclinical progress supports the target of at least two IND submissions by year-end 2022, and whether timelines or program priorities change.
- How quickly cash and investments are used as R&D, clinical preparation, staffing, and public-company expenses increase; the 12-month liquidity statement is an estimate, not a guarantee.
- Merck’s target-selection and development decisions, research funding, and the conditions required to earn potential milestones and royalties.
- Potential dilution from outstanding options, unvested shares, and automatic annual increases in equity-plan and ESPP share reserves.
- How the IPO proceeds and reported net proceeds reconcile with cash-flow reporting, including the unpaid offering costs at quarter-end.